Trastuzumab Deruxtecan Outperforms Trastuzumab Emtansine in DESTINY-Breast03 Follow-Up
December 8th 2022Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian Cancer
November 12th 2022During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.
Updates in Lung Cancer Screening Criteria Increase African American Patient Participation
July 6th 2022The expansion of screening criteria is an important step in decreasing lung cancer screening disparities in high-risk populations. Efforts to expand community outreach, overcome logistical barriers, and facilitate screening adherence must still be made, experts say.
Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLL
June 30th 2022An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial Cancer
November 21st 2021A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
Copanlisib Plus Rituximab May Be ‘Viable Option’ Across Indolent Non-Hodgkin Lymphoma
July 16th 2021More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.